# EDGAR Filing Document

**Accession Number:** 0001388658
**File Stem:** 0001388658-25-000177
**Filing Date:** 2025-7
**Character Count:** 14879
**Document Hash:** ec63b2f8b3f7abc7f0c50717b46511d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001388658-25-000177.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001388658-25-000177

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250703

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iRhythm Technologies, Inc.
- **CENTRAL INDEX KEY:** 0001388658
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208149544
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37918
- **FILM NUMBER:** 251108882

**BUSINESS ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** 415-632-5700

**MAIL ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies, Inc.
- **DATE OF NAME CHANGE:** 20110429

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies Inc
- **DATE OF NAME CHANGE:** 20070201

?xml version='1.0' encoding='ASCII'? irtc-20250703

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): July 3, 2025**

**iRhythm Technologies, Inc.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37918** | **20-8149544** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**699 8th Street, Suite 600** 

**San Francisco, California 94103** 

**(Address of principal executive office) (Zip Code)**

**(415) 632-5700** 

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, Par Value $0.001 Per Share | IRTC | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

(b) On July 3, 2025, Mark Rubash notified iRhythm Technologies, Inc. (the "Company") of his decision to resign from his position as a member of the Board of Directors of the Company (the "Board") effective July 7, 2025. Mr. Rubash's resignation from the Board was not based on any disagreement with the Company.

On July 3, 2025, Ralph Snyderman notified the Company of his decision to resign from his position as a member of the Board effective July 7, 2025. Mr. Snyderman's resignation from the Board was not based on any disagreement with the Company.

(c) Effective as of July 7, 2025, the Board appointed each of Karen McGinnis and Kevin O'Boyle as a director of the Board and member of the Audit Committee of the Board. The Board also appointed Mr. O'Boyle as a member of the Nominating and Corporate Governance Committee of the Board. Each of Ms. McGinnis and Mr. O'Boyle shall hold office for a term expiring at the 2026 Annual Meeting of the Company's stockholders.

There is no arrangement or understanding between either of Ms. McGinnis and Mr. O'Boyle and any other persons pursuant to which either Ms. McGinnis and Mr. O'Boyle was selected as a director. Neither Ms. McGinnis and Mr. O'Boyle is a party to, nor does either Ms. McGinnis and Mr. O'Boyle have any direct or indirect material interest in any transaction with the Company required to be disclosed under Item 404(a) of Regulation S-K. The Board determined that each of Ms. McGinnis and Mr. O'Boyle qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of the Nasdaq Stock Market, in each case as currently in effect and meets the further audit committee standards required by Securities and Exchange Commission ("SEC") Rule 10A-3. Each of Ms. McGinnis and Mr. O'Boyle will also enter into the Company's standard form of indemnification agreement for its directors and executive officers, which was filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1 (File No. 333-213773) filed with the SEC on September 23, 2016.

Consistent with the Company's compensation policy for non-employee directors (the "Director Compensation Policy"), upon appointment, each of Ms. McGinnis and Mr. O'Boyle was granted an initial retainer grant of restricted stock units with a fair value of $300,000 vesting annually over the three years following July 7, 2025. Each of Ms. McGinnis and Mr. O'Boyle will also receive the customary annual compensation paid to non-employee directors in the form of a cash retainer, paid quarterly in arrears, for their service on the Board and the Audit Committee in an amount consistent with the Director Compensation Policy (currently $55,000 per year for service on the Board and $10,000 per year for service on the Audit Committee, and $5,000 per year for service on the Nominating and Corporate Governance Committee in Mr. O'Boyle's case, and an anticipated grant of restricted stock units at our 2026 Annual Meeting of the Company's stockholders with a grant date fair value of $185,000, vesting on the date of the first annual stockholder meeting thereafter). The initial retainer grant will be issued under the Company's 2016 Equity Incentive Plan and will accelerate in full upon a change of control, provided that the director remains in service through such change in control.

**Item 7.01. Regulation FD Disclosure.**

The Company announced the appointment of each of Ms. McGinnis and Mr. O'Boyle to the Board in a press release furnished as Exhibit 99.1 to this Current Report on Form 8-K.

------

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release dated July 7, 2025](irtcpr_7625.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **IRHYTHM TECHNOLOGIES, INC.** | **IRHYTHM TECHNOLOGIES, INC.** |
| Date: July 7, 2025 | By: | /s/ Daniel Wilson |
|  |  | Daniel Wilson |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

![](irtcpr_7625001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iRhythm Technologies Announces Board Member Retirements and New Director Appointments SAN FRANCISCO, JULY 7, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, brought unparalleled clinical expertise and was a driving force in leading iRhythm through complex digital technology challenges early in the company's trajectory. The leaders decided to leave the board to pursue personal endeavors in their retirement. "It has been an extraordinary privilege to serve on the board of iRhythm during a period of tremendous growth and maturation," said Mr. Rubash. "I've seen firsthand how this company continues to pioneer, evolve, and put its values into action. I leave with incredible confidence in management, the board, and the company's bright future." Dr. Snyderman added, "The eight years I've spent on the board of iRhythm have provided some of the most rewarding experiences of my professional life. I'm extremely proud of what iRhythm has accomplished for the benefit of millions of patients globally and am excited to watch the company execute its long-range plan and innovate into the future." iRhythm's newly appointed board members bring deep financial expertise, business acumen, and strategic operational experience from within the medical and biotechnology industry. With their appointment to the board of directors, both Mr. O'Boyle and Ms. McGinnis have also been appointed to serve as members of the Company's Audit Committee, and Mr. O'Boyle will serve as a member of the Nominating & Governance Committee. "We are profoundly grateful to Mark and Ralph for their service, wisdom, and steadfast leadership during the better part of a decade, playing crucial roles in the establishment of iRhythm as a pioneer in ambulatory cardiac monitoring and digital health innovation," said Abhi Talwalkar, Chairman of the Board of Directors. "Their guidance has helped navigate a period of substantial company maturation while also helping to shape iRhythm's long-term vision. At the same time, we are thrilled to welcome Karen and Kevin, whose extensive experiences, global expertise, and unique insights at global medical companies will be invaluable as we enter our next phase of growth." About Karen McGinnis Karen McGinnis is an accomplished senior executive and board member with over three decades of experience leading complex international companies across biotechnology, consumer electronics, semiconductor, and technology industries. She has demonstrated expertise in driving results for organizations ranging from under $100 million to over $5 billion in annual revenue, with a proven track record in both growth and turnaround situations. Her most recent executive role was Chief Accounting Officer at Illumina, Inc. (NASDAQ: ILMN) from 2017 to 2021, where she led global accounting and tax operations for the genomics leader. Previously, she served as CEO, board member, and CFO of Mad Catz Interactive, a manufacturing gaming brand of interactive entertainment and computer products, where she successfully executed a global restructuring plan that reduced annual operating expenses and navigated complex liquidation proceedings across eight countries. Throughout her career, Ms. McGinnis has built a reputation as a hands-on leader focused on building quality teams, implementing key processes, and maintaining the highest standards of integrity and ethics. Her extensive experience spans strategic planning, acquisitions and integrations, capital raises including IPOs, SEC

------

![](irtcpr_7625002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;reporting and compliance, and international operations. McGinnis currently serves on multiple public company boards, including as board member and Audit Committee Chair at Alphatec Holdings (NASDAQ: ATEC) and Absci Corporation (NASDAQ: ABSI), where she previously served as Lead Independent Director. Ms. McGinnis holds a bachelor's degree in accounting from the University of Oklahoma and is a Certified Public Accountant. About Kevin O'Boyle Kevin O'Boyle brings over 20 years of executive leadership experience, most notably as Executive Vice President and Chief Financial Officer at NuVasive, where he helped grow the company's market capitalization from $100 million to $2 billion. Under his financial leadership, NuVasive met or exceeded Wall Street expectations for 23 consecutive quarters while achieving an average compound annual growth rate of over 45 percent and expanding Wall Street research coverage from four to 24 analysts. His executive experience also includes CFO and COO roles at Advanced BioHealing, ChromaVision Medical Systems, and Albert Fisher. Mr. O'Boyle has served on the boards of directors of multiple public companies over the past decade, notably as Chairman of GenMark Molecular Diagnostics (acquired by Roche) and Audit Committee Chair roles at Wright Medical Group (acquired by Stryker), ZELTIQ (acquired by Allergan), and Nevro (acquired by Globus Medical). He currently serves as Audit Committee Chair at Outset Medical (NASDAQ: OM) and Carlsmed. Mr. O'Boyle holds a bachelor's degree in accounting from Rochester Institute of Technology and completed executive management studies at UCLA Anderson School of Management. About iRhythm Technologies iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. Investor Contact Stephanie Zhadkevich investors@irhythmtech.com Media Contact Kassandra Perry irhythm@highwirepr.com

------